Latest News
Unplanned hospitalizations for patients with advanced cancer often trigger discussions about care goals and transitions to hospice. Late referrals to hospice, particularly near the end of life, have been associated with reduced quality of life and increased healthcare costs. A new research study published in Cancer investigates the impact of oncology hospitalists on the timing of hospice transitions for patients with advanced cancers.
- January 05, 2024Source: Oncology Learning Network
Lajos Pusztai, MD, DPhil, from Yale Cancer Center discussed results at SABCS from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.
- December 07, 2023Source: Yale Insights
Howie and Harlan are joined by Tara Sanft, chief patient experience officer at Yale’s Smilow Cancer Hospital and director of the Survivorship Program at the Yale Cancer Center.
- December 06, 2023
In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
- September 20, 2023
On Tuesday, September 19, 2023, experts from Smilow Cancer Hospital and Yale Cancer Center shared: Perspectives on the USPSTF Breast Screening Recommendations.
- September 18, 2023
Veda Giri, MD, Chief of Clinical Cancer Genetics and Co-Director of the Early Onset Cancer Program at Smilow Cancer Hospital and Yale Cancer Center, and Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology), have been named Fellows of the American Society of Clinical Oncology (FASCO).
- October 27, 2022Source: Targeted Oncology
Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.
- August 22, 2022
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.
- July 29, 2022Source: AACR
Treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy, according to phase I/II clinical trial results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
- June 16, 2022Source: Targeted Oncology
Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.